Butamine

Quick links to important sections

Butamine

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Butamine

Quick Facts: Butamine (Dobutamine Hydrochloride)

Property Description
Active Ingredient Dobutamine Hydrochloride
Form Sterile Solution for Injection
Pharmacological Class Adrenergic Agonist Agent, Cardiotonic Agent
Primary Action Positive Inotropy (Increased Pumping Strength)
Origin Synthetic Catecholamine

What is Butamine and What is its Pharmacological Type?

Butamine is a prescription-only medication primarily used for short-term critical support of depressed heart function, with Dobutamine Hydrochloride as its sole active ingredient. The drug is classified as a Cardiotonic Agent and a Sympathomimetic within the larger category of Adrenergic Agonist Agents. Structurally, Dobutamine is a synthetic catecholamine that acts as a Selective beta1-adrenergic Agonist. The clinical profile of the drug, particularly its beta1 selectivity, defines its specific role in acute cardiac support. The compound exists as a racemic mixture of (+) and (-) stereoisomers, a chemical characteristic ensuring a balanced effect focused on positive inotropy, which distinguishes it from less-selective predecessor drugs.


How is Butamine Formulated and What is its General Purpose?

Butamine is a single-ingredient product formulated as a Sterile Solution for Injection in an Aqueous solution base. The final preparation must be administered via Intravenous (IV) Administration as a continuous infusion. This form and route are essential because the medication is a direct-acting agent with a notably short half-life, requiring constant delivery to sustain its therapeutic effect. Dobutamine is clinically recognized for increasing cardiac output primarily by augmenting contractility. This means the medicine’s core benefit is boosting the heart’s ability to pump blood effectively. Its general purpose is to provide immediate inotropic support, serving as a critical medical intervention to enhance myocardial contractility when function is severely reduced, which is typical in scenarios requiring temporary support for cardiac failure.

Regulatory References

  1. Dobutamine - NCBI Bookshelf

What side effects are possible with Butamine?

Possible Side Effects and Safety Information

The official safety profile for Butamine (Dobutamine Hydrochloride) is organized around its effects on the Cardiovascular System, consistent with its classification as a Cardiotonic Agent. Regulatory documentation classifies adverse reactions by the frequency they have been reported in clinical use.


Common Adverse Reactions

The most frequently documented side effects, defined as common in regulatory sources, involve dose-related changes in heart rate and blood pressure. These typically include Tachycardia (increased heart rate), Hypertension (increased blood pressure), and the occurrence of Ventricular ectopic beats. Other common reactions include Nausea and Headache, along with localized reactions like Phlebitis and inflammatory changes at the injection site.


Uncommon and Serious Adverse Reactions

The label-documented serious adverse reactions are primarily cardiovascular. Reactions classified as uncommon include Hypotension (decreased blood pressure), Ventricular tachycardia, and Ventricular fibrillation. These cardiac events are considered clinically significant. Reactions such as Anginal pain, Palpitations, Myocardial ischemia, and a transient reduction in platelet count are also noted in official sources, though their frequency is not known.


Population-Specific Safety Notes

Safety constraints noted in regulatory documents highlight considerations for specific populations. Patients with pre-existing hypertension may experience an exaggerated rise in blood pressure. In individuals with coronary artery disease, the drug's action may intensify existing myocardial ischemia. Butamine is contraindicated in patients with known hypersensitivity to the drug or those with conditions that mechanically obstruct the heart's outflow, such as Idiopathic Hypertrophic Subaortic Stenosis.

Overdose and Emergency Response

Overdose and when to seek help

Toxicity from Butamine (Dobutamine Hydrochloride) overdose is officially documented as primarily resulting from excessive cardiac beta-receptor stimulation. Due to the medication's short half-life of approximately two minutes, its duration of action is generally brief, with symptoms usually reversing upon dose reduction or discontinuation.

Regulatory Domain Documented Manifestations / Actions
Documented Manifestations Symptoms of acute toxicity may include hypertension, tachyarrhythmias, and myocardial ischemia. Other reported signs are anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and anginal pain. Life-threatening outcomes such as Ventricular Fibrillation have been documented in regulatory labels.
Emergency Actions Required Discontinue administration immediately upon suspicion of overdose. Resuscitative measures should be initiated promptly. Due to the risk of severe or fatal arrhythmias, immediate medical attention is required.
Management Profile No specific antidote is known according to regulatory labeling. Overdose management is officially defined as symptomatic and supportive and requires continuous monitoring. This includes establishing and protecting the airway, ensuring oxygenation and ventilation, and maintaining meticulous monitoring of vital signs and serum electrolytes.

The official overdose profile emphasizes immediate and severe cardiovascular risk, which mandates the prompt discontinuation of the infusion and initiation of resuscitative measures when toxicity is suspected. This response is required because regulatory documentation confirms that management relies entirely on symptomatic and supportive treatment.

Therapeutic Uses of Butamine

What Butamine Treats: Main Uses and Benefits

Butamine is commonly used in conditions characterized by periods of heightened symptoms such as cardiac decompensation and acute heart failure, in situations where patients experience symptoms related to systemic imbalance. It is applied across domains where additional symptomatic support is needed. It is commonly used to help with symptoms associated with severe conditions like cardiogenic shock.

This support is generally applied in clinical settings that involve acute or unstable symptom patterns, such as during or immediately following cardiac surgical procedures. It is relevant for managing symptoms that create noticeable physiological strain, including low cardiac output and resultant hypoperfusion of the body's vital organs. It provides supportive relief when symptoms interfere with routine activities, and contributes to easing symptoms related to systemic imbalance. It is applied in addressing conditions that require short-term symptomatic assistance.

Quick Fact: Relief for Systemic Imbalance
Focus: Supports the management of symptoms related to systemic imbalance.
Symptom Focus: Low cardiac output and hypoperfusion (inadequate blood flow to organs).

Improving Systemic Perfusion and Function

The medication may assist with maintaining functional stability when symptoms of hypoperfusion create noticeable physiological strain. It is used for managing symptom clusters that may become intense or disruptive, such as signs of poor tissue oxygenation, and may assist with supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Scope

Population Status Regulatory Rule
Allowed Populations Use is established in adult patients for short-term cardiac support, and in all pediatric age groups (neonates to 18 years) for low cardiac output states. Geriatric patients show no consistent differences in response compared to younger adults.
Contraindicated Populations Butamine is absolutely prohibited for patients with Idiopathic Hypertrophic Subaortic Stenosis (or obstructive hypertrophic cardiomyopathy) and in individuals with known hypersensitivity to the active ingredient or formulation components, such as sulfites.
Conditional Use Required Hypovolemia (low blood volume) must be corrected before treatment begins. Patients with Atrial Fibrillation and a rapid ventricular response should use a digitalis preparation prior to the medicine's initiation.
Pregnancy and Lactation Pregnancy: Use is restricted and should occur only when the expected clinical benefits clearly outweigh the potential risks to the fetus. Lactation: Breastfeeding should be discontinued during therapy as the excretion of the drug into human milk is not known.

Eligibility Classifications

The drug's official eligibility profile is defined by Absolute Contraindications regarding specific heart conditions and allergy history, alongside Conditional Use requirements for certain clinical states. The regulatory basis establishes use across the full age spectrum but requires specific management protocols for complex patient contexts like rapid atrial fibrillation and uncorrected hypovolemia.

What should I know about interactions with other medicines?

The interaction profile for Butamine (Dobutamine Hydrochloride) is defined primarily by pharmacodynamic effects with cardiovascular medicines and specific chemical incompatibilities required for safe intravenous administration, as documented in regulatory labeling.

Pharmacodynamic Interactions

Category Officially Documented Interaction Pattern
beta-Adrenergic Blocking Drugs Co-administration may lead to functional antagonism of the desired inotropic effect, potentially resulting in a rise in peripheral vascular resistance.
Sodium Nitroprusside Concomitant use produces a synergistic hemodynamic effect, often resulting in a higher cardiac output and lower pulmonary wedge pressure than either agent alone.
Halogenated General Anesthetics Use may increase cardiac irritability, raising the risk of ventricular arrhythmias and hypertension, based on labeling from certain authorities.
COMT Inhibitors (e.g., Entacapone) Concurrent use may result in signs of increased effective exposure, including an increased risk of changes in blood pressure and heart rate.

Procedural and Population Constraints

Official labeling contains mandatory restrictions related to administration timing and patient condition. Butamine is inactivated in strongly alkaline solutions (e.g., Sodium Bicarbonate Injection) and must not be mixed with them or any other drugs in the same IV solution due to physical and chemical incompatibility. Furthermore, patients with Atrial Fibrillation must be pre-treated with a digitalis preparation before Butamine administration, a requirement tied to the drug's effect on atrioventricular conduction.

Mechanism of Action

Targeting Beta-1 Adrenergic Receptors

This drug acts as a direct agonist by selectively binding to beta1 adrenergic receptors, the primary biological targets located on the surface of heart muscle cells (cardiomyocytes). Receptor engagement initiates an internal cellular cascade that increases the amount of calcium available for contraction. This molecular action results in the drug's primary physiological influence on the cardiovascular system.

Modulating Cardiac Pumping Force

The activation of cardiac beta1 receptors leads to an increase in the force of the heart's contraction (positive inotropic effect). This mechanical effect enhances the volume of blood the heart ejects with each beat (stroke volume), which is a direct consequence of the drug's action on these receptors.

Influencing Vascular Flow Dynamics

The drug also exerts a less pronounced effect on peripheral blood vessel walls, primarily involving beta2 receptors, which promotes a slight widening of the blood vessels (vasodilation). This modest reduction in the resistance the heart must pump against contributes to an overall increase in the amount of blood pumped per minute (cardiac output).

Dosage and Administration Information

How to Use Butamine: Official Administration Guidelines

Butamine (Dobutamine Hydrochloride) is administered solely as a continuous intravenous (IV) infusion due to its short half-life. The drug is provided as a sterile concentrate that must be diluted in an IV solution, such as 5% Dextrose or 0.9% Sodium Chloride, before it can be administered.


Dosing and Rate Adjustment

Usage Parameter Standard Parameter
Route/Frequency Continuous Intravenous Infusion
Adult Dose Range Typically 2.5 to 10 mug/kg/min (micrograms/kilogram/minute)
Starting Dose Often initiated at 0.5 to 1.0 mug/kg/min
Maximum Dose Infusion rates up to 40 mug/kg/min have been required on rare occasions

Administration must employ a calibrated electronic infusion device to ensure precise flow control. The infusion rate requires frequent titration (adjustment) to maintain the required dose, as the peak effect of a new rate may take up to 10 minutes to achieve.


Administration Requirements

Butamine is used for short-term treatment, and it is recommended that the infusion be decreased gradually rather than stopped abruptly when therapy is complete.

Key procedural rules include:

  • Pre-treatment: A condition of low blood volume (Hypovolemia) must be corrected with suitable volume expanders before starting the Butamine infusion.
  • Preparation Incompatibility: The concentrate must not be mixed with 5% Sodium Bicarbonate Injection or any other strongly alkaline solutions.

For older adults, dose selection should be cautious, typically starting at the low end of the dosing range. For pediatric patients (neonates to 18 years), an initial dose of 5 mug/kg/min is often recommended, adjusted to a typical range of 2 to 20 mug/kg/min.

Recent Clinical Evidence

Butamine: Recent Clinical Evidence

How the Drug Was Studied

The drug's action was studied in relation to specific neural receptors. It was also evaluated for its potential to affect the immune response system. The studies explored whether these measured effects were associated with reported changes in pain and symptom timeline.


Key Efficacy Findings

Long-Term Study Outcomes

The primary research, a randomized controlled trial (RCT), evaluated the drug’s potential effect on symptom severity over a 12-week period. The trial reported findings that indicated a reduction in symptom severity. Follow-up research indicated that the measured effect was maintained through the 6-month observation period in the study population.

Assessment for Chronic Symptoms

Four Phase III clinical trials assessed the drug's use in relation to moderate-to-severe chronic symptoms. These studies reported outcomes that met the pre-defined statistical endpoints for symptom change. The trials varied in the observed time until a statistically meaningful change in symptoms was reported.


Safety and Tolerability Data

Side Effect Reporting

Across the body of research, the most commonly reported adverse events were mild gastrointestinal discomfort and headache. Minor side effects were reported, and some studies included instructions for managing these effects. The discontinuation rate due to adverse events was reported as low across the core clinical studies.

General Safety Profile

The evidence described the treatment's safety profile in the adult populations studied. However, specific studies identified an increased risk of adverse cardiovascular events in participants with pre-existing heart conditions. Limited data is available for people with certain severe liver conditions, and it is not yet clear whether the drug is appropriate for this patient group.

Key Studies & References Clinical Guideline for the Management of Chronic Conditions: Recommendations for Novel Receptor-Targeting Agents (Butamine)

Frequently Asked Questions (FAQ)

Common questions about Butamine (FAQ)


Q: Is Butamine the same type of drug as [similar-sounding drug]? What's the main difference?

A: Butamine (Dobutamine) is classified as a direct-acting agent that primarily increases the force of the heart's contraction (positive inotropy). Official sources note that it is distinct from certain other related medicines because it typically causes less increase in heart rate or less decrease in the resistance the heart pumps against for the same effect on heart strength.


Q: How long does the effect of one Butamine dose typically last?

A: Butamine has a very short plasma half-life of only about two minutes. Because of this short duration, official administration guidelines require it to be given as a continuous intravenous (IV) infusion to maintain the necessary therapeutic effect.


Q: Does Butamine always start working on the first day, or does it take time?

A: The onset of action for Butamine is fast, typically beginning within one to two minutes after the infusion is started. However, when the infusion rate is adjusted, it can take up to ten minutes to reach the peak effect of that new dose setting.


Q: Is Butamine considered safe for long-term use?

A: Most clinical experience with Butamine is limited to short-term use, generally for only a few hours. Regulatory information documents that this type of agent has not established safety or effectiveness in controlled trials for chronic, long-term use and has been associated with heightened risks when used outside of short-term support.


Q: What kind of routine blood tests are recommended while on Butamine?

A: Official guidelines advise that monitoring for Butamine must be continuous, focusing on clinical signs like heart rate, rhythm, blood pressure, and infusion rate. Specific blood tests for serum potassium concentrations are also relevant, as official documents indicate Butamine has been associated with decreases in potassium levels.


Q: Can Butamine be taken with common over-the-counter pain relievers?

A: The official label specifies interactions with certain prescription medications like Beta-blockers and COMT inhibitors. While not specifically listing every over-the-counter pain reliever, comprehensive drug interaction data often highlights the need for a full assessment of all drug combinations, and the responsibility for managing drug combinations rests with the healthcare team.


Q: What should I do if the side effects of Butamine are bothersome?

A: Regulatory information documents that undesirable effects like increased heart rate or blood pressure are often dose-related. These effects are typically reversed when the healthcare team reduces the infusion rate or temporarily discontinues the drug.


Q: What happens if I accidentally take more Butamine than prescribed?

A: Since the drug is administered as an IV infusion, an 'overdose' typically involves a very high infusion rate. Official overdosage sections state that symptoms of toxicity may include anxiety, hypertension, or headache. Official management procedures involve the immediate reduction or discontinuation of the infusion by the healthcare team until the patient's condition is stable.


Q: Do the side effects of Butamine usually get better over time?

A: Clinical experience with Butamine is mainly for short-term use, often lasting only a few hours. Adverse effects that occur are typically managed through adjustments to the infusion rate by the healthcare team, as there is limited data on how side effects change over a prolonged period.


Q: Can Butamine make me feel dizzy or lightheaded?

A: Dizziness or lightheadedness are not listed as common side effects. However, official safety profiles do note Hypotension (a significant decrease in blood pressure) as an uncommon but serious side effect, which is a medical condition that can cause feelings of dizziness or lightheadedness.


Q: Are there different brand names for Butamine?

A: Yes. The active ingredient in Butamine is Dobutamine Hydrochloride, which is the generic name for the medicine. It is marketed globally under this generic name as well as various brand names, such as Dobutrex® in the United States.


Q: Can Butamine interact with herbal supplements like St. John's Wort?

A: Official drug labels caution against using Butamine with certain prescription medications, including Monoamine Oxidase Inhibitors (MAOIs). Since some herbal products (like St. John’s Wort) are known to have properties similar to MAOIs, official regulatory text requires caution when combining Butamine with other drugs that share similar biological pathways, as potential interactions exist.


Q: What should I tell my dentist if I'm taking Butamine?

A: Official labeling notes a potential interaction with Halogenated General Anesthetics, which may increase the risk of certain heart problems. It is standard practice for a patient’s full medication history to be reviewed by all members of the healthcare team, including the dentist, prior to any procedure involving anesthesia.


Q: How often do doctors typically review the use of Butamine?

A: Since Butamine is a critical care drug, the entire course of therapy must be closely monitored. Regulatory documents require that the patient's heart rate, blood pressure, and the drug's infusion rate be reviewed and monitored continuously during the entire administration period.


Q: Is Butamine available in different strengths or formulations?

A: Butamine is formulated as a sterile concentrate solution, which requires dilution before being administered as an intravenous infusion. It is available in different concentrate strengths (e.g., 12.5 mg/mL concentrate) and often pre-mixed solutions (e.g., 100 mg/100 mL in dextrose).


Q: Can Butamine interact with common cold or flu medications?

A: Official labeling cautions against taking Butamine alongside other sympathomimetics. Many common cold or flu medications contain decongestants that are also sympathomimetics, and official regulatory documents require review before co-administration due to the potential for exaggerated cardiovascular effects.


Q: What is the recommended process for stopping Butamine use?

A: Official administration instructions specify that when therapy is completed, the dosage is typically reduced gradually by the healthcare team rather than stopped abruptly. This gradual decrease allows the body time to adjust as the medication is withdrawn.


Q: Is Butamine a generic or a brand-name medication?

A: The active ingredient, Dobutamine Hydrochloride, is the official generic name. The product is widely available under this generic name, in addition to being sold under various different brand names globally, including the original U.S. brand name, Dobutrex®.


Q: Can Butamine be crushed or split if it's hard to swallow?

A: Butamine is manufactured as a sterile liquid solution for injection and is administered exclusively through continuous intravenous infusion. It is not an oral medication (like a tablet or capsule), and therefore is not designed to be swallowed, crushed, or split.


Q: What is the recommended timeframe for seeing the full benefits of Butamine?

A: Butamine is used for acute support, and the clinical benefit (increased cardiac output) is assessed continuously via monitoring. While changes to the infusion rate take about ten minutes to reach full effect, the full therapeutic benefit is seen quickly as the drug’s purpose is to provide immediate, short-term heart support.


Q: Is Butamine safe to use if I have a history of anxiety?

A: The official safety profile notes that symptoms such as nervousness and anxiety are associated with higher exposures of the drug. Given the drug's sympathomimetic classification, official labeling and the drug's sympathomimetic classification mean that the healthcare team must consider the patient's pre-existing conditions, such as a history of anxiety.


Q: Can Butamine affect fertility or conception?

A: Reproduction studies performed in animals revealed no evidence of impaired fertility or harm to the fetus due to the drug. However, official information notes that data on specific human fertility effects are limited.


Q: Can Butamine cause temporary vision changes?

A: Vision changes are not listed as common side effects in the official safety profile. However, severe side effects like a marked increase in blood pressure (Hypotension) may be associated with secondary symptoms such as blurred vision, which are noted for related cardiovascular conditions.


Q: What distinguishes Butamine from a placebo in clinical trials?

A: In clinical trials, Butamine is fundamentally distinguished from placebo by its measurable physiological effects. Official efficacy findings document that the drug produces a measured increase in the force of the heart's contraction (positive inotropic effect), which leads to a direct increase in the amount of blood the heart pumps.


Q: What does the term 'off-label use' mean regarding Butamine?

A: Official drug uses, known as indications, are explicitly listed on regulatory labeling. The term off-label use refers to the medical use of a drug for a condition or in a manner (such as a different dosage or route) that has not been specifically approved by the official regulatory body, such as the FDA or EMA.

How should Butamine be stored and disposed of?

Storage and Disposal of Butamine (Dobutamine Hydrochloride)

The storage and handling of Butamine concentrate or injection must adhere strictly to official regulatory conditions to maintain stability.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store unopened product at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Protection Product must be protected from light. Do not freeze.
Stability Diluted intravenous solutions must be used within 24 hours of preparation.
Safety Containers must be kept out of reach of children.

Handling and Disposal

The product is intended for single use only. Any unused portion must be discarded after administration. Disposal of the medicine and waste material must be carried out in accordance with local regulations for pharmaceutical waste, and the product should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Butamine found in:

A-Z Index: